



250 Industry Drive
Pittsburgh, PA 15275

revvity.com

November 6, 2025

Revvity Omics continues to invest in laboratory testing platforms and recently validated several assays on Genetic Screening Processors (GSPs). The instrument is an automated high throughput platform for screening disorders in newborns using both DELFIA immunoassay and enzymatic technologies.

Disorders include:

- Biotinidase
- Congenital Adrenal Hyperplasia
- Congenital Hypothyroidism
- Cystic Fibrosis
- Galactosemia

Starting in **early 2026**, the lab will switch to the GSP platform for Congenital Hypothyroidism (TSH) and Congenital Hypothyroidism (T4) testing. Note that cutoffs and algorithms will remain the same, so **no action is required**.

Then, starting in **April 2026**, the lab will start utilizing the GSP platform for testing Biotinidase, Congenital Adrenal Hyperplasia, Cystic Fibrosis, and Galactosemia. **This switch will introduce new cutoffs**. We will be in touch soon to discuss any software updates that may be required such as interfaces and portal reports.

Please let us know if you have any questions by sending an email to RevvityGenetics.Information@Revvity.com or by calling +1 (866) 354-2910.

Sincerely,

The Revvity Omics Team